J 2018

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

MYTSYK, Yulian, Victor DOSENKO, Yuriy BORYS, Askold KUCHER, Katarina GAZDIKOVA et. al.

Basic information

Original name

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

Authors

MYTSYK, Yulian (804 Ukraine), Victor DOSENKO (804 Ukraine), Yuriy BORYS (804 Ukraine), Askold KUCHER (804 Ukraine), Katarina GAZDIKOVA (703 Slovakia), Dietrich BUSSELBERG (634 Qatar), Martin CAPRNDA (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution), Ammad Ahmad FAROOQI (586 Pakistan) and Manyuk LUBOV (804 Ukraine)

Edition

International Urology and Nephrology, Dordrecht, Springer, 2018, 0301-1623

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30217 Urology and nephrology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.596

RIV identification code

RIV/00216224:14110/18:00102916

Organization unit

Faculty of Medicine

DOI

UT WoS

000431429000008

Keywords in English

Renal cell carcinoma; MiRNA-15a; Biomarker; Diagnosis; Molecular marker

Tags

Tags

International impact, Reviewed
Změněno: 10/2/2019 16:07, Soňa Böhmová

Abstract

V originále

Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 +/- 2.72E-01 vs 1.32E-03 +/- 3.90E-03 vs 3.36E-07 +/- 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.